S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA
Main Authors: | M. C. Pirosa, A. Bruscaggin, L. Terzi di Bergamo, M. Salehi, K. Pini, V. Spina, S. Bocchetta, A. Condoluci, G. Forestieri, D. Piffaretti, J. Marques De Almeida, S. Annunziata, F. Bergesio, E. Borsatti, P. Bulian, S. Chauvie, C. Marco, D. T. Martina, G. Bernhard, M. Kurlapski, A. Moccia, R. Moia, A. Rinaldi, M. Rodari, G. Romanowicz, G. M. Sacchetti, A. Stasia, A. Stathis, G. Stüssi, I. Zangrilli, L. M. Larocca, A. Pinto, A. Santoro, F. Cavalli, E. Zucca, V. Gattei, J. M. Zaucha, C. Carlo-Stella, S. Hohaus, G. Gaidano, L. Ceriani, D. Rossi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843792.32037.28 |
Similar Items
-
A Rare Case of Life-Threatening Jaundice Caused by Epstein-Barr Virus Infection and Secondary Cold Agglutinin Syndrome Successfully Treated with Rituximab
by: Bellia M, et al.
Published: (2024-10-01) -
The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials
by: Stephane Chauvie, et al.
Published: (2016-11-01) -
Device-to-Device Communications for 5G Internet of Things
by: L. Militano, et al.
Published: (2015-10-01) -
Liquid biopsy in lymphoma
by: Davide Rossi, et al.
Published: (2019-04-01) -
P834: REAL-WORLD EVIDENCE OF SAFETY AND EFFECTIVENESS OF ECULIZUMAB AND SWITCH TO RAVULIZUMAB IN A SWISS PATIENT POPULATION WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
by: A. Rovó, et al.
Published: (2022-06-01)